



News Release

Execution of Term Loan Credit Agreement for Shire plc Acquisition

Osaka, Japan, June 8, 2018 --- Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka, the “**Company**” or “**Takeda**”) announces that it has entered into a “**Term Loan Credit Agreement**” (the “**Term Loan Credit Agreement**”) for an aggregate principal amount of up to 7.5 billion U.S. dollars to finance a portion funds necessary for the acquisition of Shire plc (“**Shire**”) and to reduce commitments under the a “**364-Day Bridge Credit Agreement**” entered into in connection with the Acquisition on 8 May 2018 (the “**Bridge Credit Agreement**”).

1. Details of Term Loan Credit Agreement

(a) Borrower	Takeda Pharmaceutical Company Limited
(b) Administrative Agent	JP Morgan Chase Bank, N.A.
(c) Arrangers	JP Morgan Chase Bank, N.A. Sumitomo Mitsui Banking Corporation MUFG Bank, Ltd. Mizuho Bank, Ltd.
(d) Execution date of agreement	June 8, 2018
(e) Total borrowing limit	7.5 billion U.S. dollars, of which up to 3.5 billion U.S. dollars may be available in euros
(f) Interest rate	Adjusted LIBOR rate plus an applicable margin based on public debt rating
(g) Use of proceeds	Payment of a portion of the Acquisition cash consideration and related fees, costs and expenses incurred by Takeda
(h) Tenor	5 years
(i) Pledge	None

(j) Security	None
(k) Governing Law	New York

2. Impact on the financial results for the fiscal year ending March 2019

Upon the execution of the Term Loan Credit Agreement, the commitments under the Bridge Credit Agreement will be reduced on a dollar-for-dollar basis by up to 7.5 billion U.S. dollars. We will announce the impact of the Term Loan Credit Agreement on our business performance promptly after we estimate it.

Media Contacts:

Japanese Media

Kazumi Kobayashi

kazumi.kobayashi@takeda.com

+81 (0) 3-3278-2095

###